Volume 17, Issue 4 (Autumn 2026)                   Caspian J Intern Med 2026, 17(4): 16-0 | Back to browse issues page

Ethics code: IR.SBMU.MSP.REC.1403.594

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salimi M, Salimi B, Rezvani H, Pourghasemian M, Beyramzadeh E, Mirzaei M H et al . Safety and Outcomes of Etoposide as a Substitute for Radiotherapy in Primary mediastinal B-cell lymphoma Treatment. , Caspian J Intern Med. 2026; 17 (4) :16
URL: http://caspjim.com/article-1-5083-en.html
Shahid Beheshti University of Medical Sciences, Tehran, Iran , salari.sina52@gmail.com
Abstract:   (53 Views)
Background: Primary mediastinal B-cell lymphoma (PMBCL) is a unique subtype of diffuse large B-cell lymphoma. There are some concerns regarding the long-term toxicity of radiotherapy treatment. We compared clinical outcomes and recorded adverse events between DA-EPOCH-R without planned radiotherapy and R-CHOP followed by mediastinal consolidation.
Methods: Medical records of 91 adults with PMBCL treated at Dr. Masih Daneshvari Hospital between 2019 and 2024 were retrospectively reviewed. Forty-six patients received DA-EPOCH-R without planned radiotherapy, whereas 45 received R-CHOP followed by mediastinal radiotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were three-year overall survival (OS), complete metabolic response (CMR), defined as a Deauville score of 1–3 on PET-CT performed three months after treatment completion, and documented adverse events.
Results: Median PFS was 12 months in the DA-EPOCH-R group and 13 months in the R-CHOP plus radiotherapy group (log-rank p=0.808). Treatment regimen was unrelated to PFS after adjustment for age and sex (adjusted HR, 1.03; 95% CI, 0.66–1.61; p=0.884).Three-year OS was 91.3% versus 93.3% (p=0.716), and CMR rates were 87.0% versus 95.6% (p=0.148), respectively. Fever and neutropenia were less frequently documented in the DA-EPOCH-R group (p=0.019 and p=0.001, respectively).
Conclusion:  PFS, three-year OS, and CMR did not differ significantly between the treatment strategies. Fever and neutropenia were less frequently documented with DA-EPOCH-R.
     
Policy Brief: Original Article | Subject: Oncology
Received: 2026/02/15 | Accepted: 2026/11/10 | Published: 2026/09/9

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Caspian Journal of Internal Medicine

Designed & Developed by: Yektaweb